Biotech Stocks Blasts Off After Eczema Drug Trial

Biotech stock Nektar Therapeutics Inc (NASDAQ:NKTR) is soaring today, up 83.7% at $17.52 at last glance, after the company's eczema drug, rezpegaldesleukin, met its primary and secondary goals in a mid-stage study. NKTR is now headed for its best day since a 91.5% pop on August 7, 2023 (which occurred after promising data for the same drug). Breaking above several layers moving averages, including the 320-day trendline that kept a lid on mid-February gains, NKTR is now up 23.7% in 2025. Options traders are ...